Lanreotide Acetate Injection
Product Images NDC 69097-880

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 69097-880). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lanreotide Acetate 01)

The text appears to be a chemical formula with specific amino acid sequences and a variable X represented with a range of 1.0 to 2.0 that is multiplied by CH:COOH. It is likely a formula for a peptide.*

FDA Label Image

Figure 1 (Lanreotide Acetate 02)

This is a graph showing the Progression-free Survival Probability (%) of subjects taking Somatuline Depot compared to Placebo. The graph also includes the Hazard Ratio (HR = 0.47) and the 95% confidence interval (0.30 - 0.73) with a p-value of less than 0.001. The number of subjects still at risk is displayed on the right-hand side and time in months is displayed on the bottom.*

FDA Label Image

Fig 1 (Lanreotide Acetate 03)

This appears to be a description of a needle pack containing a syringe. The pack includes a green needle shield, barrel, collar, and cap along with a plunger. The needle is presumably included within the pack as well. The accompanying figure may provide additional details on the organization and layout of the pack.*

FDA Label Image

Fig 2 (Lanreotide Acetate 04)

This is a product for the medical field that includes a clear needle cap with a green retractable shield for protection. The needle is visible through a round window for ease of use. Additionally, a needle pack is included with the needle already inside.*

FDA Label Image

Fig 3 (Lanreotide Acetate 05)

FDA Label Image

Fig 4 (Lanreotide Acetate 06)

FDA Label Image

Fig 5 (Lanreotide Acetate 07)

FDA Label Image

Fig 6 (Lanreotide Acetate 08)

FDA Label Image

Fig 7 (Lanreotide Acetate 09)

FDA Label Image

Fig 8 (Lanreotide Acetate 10)

FDA Label Image

Fig 9 (Lanreotide Acetate 11)

FDA Label Image

Fig 10 (Lanreotide Acetate 12)

FDA Label Image

Fig 11 (Lanreotide Acetate 13)

FDA Label Image

Fig 12 (Lanreotide Acetate 14)

FDA Label Image

Fig 13 (Lanreotide Acetate 15)

FDA Label Image

Fig 14 (Lanreotide Acetate 16)

FDA Label Image

Fig 15 (Lanreotide Acetate 17)

FDA Label Image

Fig 16 (Lanreotide Acetate 18)

FDA Label Image

Fig 17 (Lanreotide Acetate 19)

FDA Label Image

Fig 18 (Lanreotide Acetate 20)

The text is a cautionary message regarding a green needle shield, instructing not to touch it, and clarifying that it is not a cap. It is accompanied by a reference to "Figure 13", which is not available for interpretation without further context or information.*

FDA Label Image

Fig 19 (Lanreotide Acetate 21)

FDA Label Image

Fig 20 (Lanreotide Acetate 22)

FDA Label Image

Fig 21 (Lanreotide Acetate 23)

This text is a notice or warning about the importance of maintaining a 90-degree angle during a subcutaneous injection to achieve the correct depth. There is a reference to Figure 16, which may provide visual guidance or further information.*

FDA Label Image

Fig 22 (Lanreotide Acetate 24)

FDA Label Image

Fig 23 (Lanreotide Acetate 25)

Attention: Full retraction of the green needle shield is critical to ensure proper injection depth. Figure 18.*

FDA Label Image

Fig 24 (Lanreotide Acetate 26)

FDA Label Image

Fig 25 (Lanreotide Acetate 27)

FDA Label Image

Fig 26 (Lanreotide Acetate 28)

FDA Label Image

Fig 27 (Lanreotide Acetate 29)

FDA Label Image

Fig 28 (Lanreotide Acetate 30)

FDA Label Image

60 mg/0.2 mL Carton Label (Lanreotide Acetate 31)

This is a product description for Lanreotide Injection, a medication provided in 60 mg syringes for deep subcutaneous injection. Each syringe also contains Lanreotide acetate and cumon water for injection. The recommended dosage is provided separately, and it should be stored in a refrigerator at 2°C t0 8°C to protect the medication from light. The product is manufactured by Pharmathen International, S.A. in Rodopl, Greece, and is distributed by Cipla USA, Inc. The box includes one pre-filled syringe and a safety needle. If there are any questions about the medication, please call 1-866-604-3268.*

FDA Label Image

90 mg/0.3 mL Carton Label (Lanreotide Acetate 32)

Lanreotide Injection is a prescription medication administered through deep subcutaneous injection. Each syringe contains 90 mg of Lanreotide acetate in 0.3 ml of water for injection. It is recommended to store the medication in a refrigerator between 2°C to 6°C and protect it from light. The medication is manufactured by Resmathen Itomatona S.A. in Greece and marketed by Cipla USA, Inc. The box contains one prefilled syringe and one safety needle. If there are any questions related to Lanreotide injection, please contact the manufacturer.*

FDA Label Image

120 mg/0.5 mL Carton Label (Lanreotide Acetate 33)

Lanreotide Injection is a prescription medication that contains Lanveolide 120 mg as Lanreotide acetate. A syringe of the medication includes 0.5 mL of a solution containing 120 mg of lanreotide base provided as lanreotide acetate in water. The medication is intended for deep subcutaneous administration by a healthcare professional, and the single-dose only product must be discarded if unused. A prefilled syringe and a safety needle are included in the pack. Lanreotide injection should be kept in its original box, in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. The manufacturer is Pharmathan International, S.A. and has been manufactured for Cipa USA, Inc. Contact 1.866-604.3263 for any questions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.